Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test

The concept of prescription drug affordability boards is being increasingly explored by US state lawmakers who have become frustrated at Washington's lack of progress in addressing drug pricing. Although the Biden administration succeeded in making it possible for the Medicare program to negotiate prices, the initiative applies only to a small number of medicines each year and does not include the costs borne by Americans with private health insurance.

Yet various efforts by state governments over the years to combat prescription drug costs have met with fierce pushback from the pharmaceutical industry. Beyond lobbying to water down or kill legislation, industry trade groups have often filed lawsuits